149 related articles for article (PubMed ID: 24729186)
21. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
22. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
23. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
Yuan BJ; Liu ZZ; Ding XR; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of soluble Fas ligand as a serological marker for melanoma.
Melzani G; Bugari G; Parrinello G; Mori G; Manganoni Au; De Panfilis G
Dermatology; 2002; 205(2):111-5. PubMed ID: 12218223
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of interleukin-22 in multiple myeloma.
Tsirakis G; Pappa CA; Kolovou A; Kokonozaki M; Neonakis I; Alexandrakis MG
Hematology; 2015 Apr; 20(3):143-7. PubMed ID: 25055724
[TBL] [Abstract][Full Text] [Related]
26. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.
Tsirakis G; Pappa CA; Kaparou M; Katsomitrou V; Hatzivasili A; Alegakis T; Xekalou A; Stathopoulos EN; Alexandrakis MG
Eur J Histochem; 2011; 55(3):e21. PubMed ID: 22073368
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
Soni S; Rath G; Deval R; Salhan S; Mishra AK; Saxena S
Am J Reprod Immunol; 2011 Sep; 66(3):230-6. PubMed ID: 21385271
[TBL] [Abstract][Full Text] [Related]
28. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
29. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
31. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis.
Katsaros KM; Wiesbauer F; Speidl WS; Kastl SP; Huber K; Zorn G; Niessner A; Glogar D; Maurer G; Wojta J
Thromb Haemost; 2011 May; 105(5):883-91. PubMed ID: 21359408
[TBL] [Abstract][Full Text] [Related]
32. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
33. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
34. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
[TBL] [Abstract][Full Text] [Related]
35. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
37. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma.
Alexandrakis MG; Goulidaki N; Pappa CA; Boula A; Psarakis F; Neonakis I; Tsirakis G
Pathol Oncol Res; 2015 Sep; 21(4):929-34. PubMed ID: 25743259
[TBL] [Abstract][Full Text] [Related]
39. Soluble Fas: a novel predictor of atherosclerosis in dialysis patients.
Troyanov S; Hébert MJ; Masse M; Vigneault N; Sirois I; Madore F
Am J Kidney Dis; 2003 May; 41(5):1043-51. PubMed ID: 12722039
[TBL] [Abstract][Full Text] [Related]
40. Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease.
Góes MA; Dalboni MA; Manfredi SR; Cendoroglo MS; Batista MC; Canziani ME; Balakrishnan VS; Pereira BJ; Draibe SA; Cendoroglo M
Clin Nephrol; 2010 Jan; 73(1):7-13. PubMed ID: 20040346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
